Member Info for Tambo210

Anton : "The presentation today still stated they have multiple parties interested."

Of course they're going to say that. You'd trash your stock price if you said "No one's interested in this field. We're left on our own!"

LawrenceH

When did it last reach 300p?

It can be undervalued (which I agree), but its just a PT. Their has to be more buyers than sellers.

LGEN is a stock you bag 8pc+ yield. Don't expect growth. you might get 260p as it approaches ex-div.

Defo more realistic that 300p+

Wow! $107 call option without paying a premium

Lordloadsoflolly - I actualy hold my OEICS and inv trust in Fidelity.

Its marginally higher than HL.

My wife has a small amount (2% (Flat £90)

Mad drop, but let's face it...they've been shafted by the Tories in the quest to appease UK population.

Bigger oil co's making more profits than HBR, but their operations are elsewhere. Hence they don't get taxed as heavily.

How much money did they actually raise with the windfall tax and what proportion of the worst offenders paid up to make a difference?

Tories have alienated Oil companies from investing in UK oil production. We'll never be energy independent if you p!ss of the private companies that have the expertise to extract the stuff out of the seabed which your population can't wean itself off.

As for renewables, Oil companies are part of the solution not the only the problem. By incentivising them to invest in renewable schemes, longer term, the population benefits. They tried to help the UK population short-term, but actually, it hasn't worked and the Tories have had to borrow more money to pay for the energy allowance.

Energy trades on the open market and should be interfered with by the government, else it gets distorted.

Cruel as it sounds, we as a population sometimes have to make hard decisions, and stick on a jumper or three, rather than feel entitled to subsidies. The Energy subsidy was offered to all households. How stupid is that! Help the people that most need it, and sadly, others have to pay a bit more. Demand - supply will balance if necessary.

Barclays raises Legal & General price target to 333 (330) pence - 'overweight'

Like I said. 12m PT for me is 275p. More realistic.

Once you writedown COVID related revenue to zero, we can look at the business on normal terms.

COVID testing was always going to wane. Its whether they can use the one-time COVID money to advance their products and research elsewhere.

Thanks all.

Looks like I need to review HL as an alternative to Fidelity and swap across. Only hold LGEN and MNG as shares, and then oeics.

I have a few of Fidelities Select 50 to get a discount, but can't help notice the frequency and amount of their charges vs the size of my holding. PLUS their commission on buying/selling shares hurts.

Gotoutjustintime

Thanks for sharing.

I'm trying to rebalance one of my portfolios and my kids' ones so I really don't need to meddle with them.

They're quite young, so have plenty of time to build up their reserves.

Mine is a bit of a mish-mash with no consistency with my aim. I'm seeing the benefit in LGEN and MNG. Just don't want to be too focussed on just those 2.

SGE might be another to balance it out + a pharma.

Thing that peeves me is the high cost of buying stock in the UK.

I read a telegraph article that Fidelity was one of the highest charging providers. I'm trying to port my ISA away from them, but need to find something with the same access to funds.

Just need some time to research this.

I also have a halifax trading account, but don't like the idea of paying double fees.

@anton

You bailed?

OMG!

Welcome to the world of investing in Africa and the Middle East.

Over my 20 years of investing in stocks there, I've learnt to temper my enthusiasm when it comes to positive sounding news.

So what's your stance on Kenya? They haven't suffered a coup.

@Canchat

Believe it or not, I actually like what this company is. Produces something tangible, pays a dividend (not sure about the cover though), their products are in need and from markets I'm aware of, demand is only going to increase assuming they can go out and win market share. They have products which people need, just can they aggressively market them?

The negatives on this company are that their management seems a little laid back. The Security breach for example is not a new thing. This sort of thing has been happening for donkey's years. If they had a breach, it shouldn't have even made the news because it was locked down quickly. What the RNS shows is there's a lack of investment in the right places and management are responsible for that.

As well, I hope they're sensible with their divi. By that I mean they're not afraid to adjust if cash flow is falling or negative. I hope the don't borrow to pay it.

As with all investments, only bet what you can afford to lose.

Berenberg raises Legal & General price target to 258 (254) pence - 'hold'

Sugarbabe "And I say this too...the only.fund to make me.some.decent return is that Legal & General Global technology fund..."

I don't have the spare funds to move into this fund atm. Its performance has been undisputable.

Looking at the holdings (Top 10)

Top 10 holdings (%)

Apple 19.6

Microsoft 17.3

Nvidia 6.8

Alphabet A 4.9

Meta Platforms A 4.3

Alphabet C 4.3

Taiwan Semiconductor Manufacturing Co 3.0

Broadcom 2.4

ASML 2.0

Adobe 1.5

They're all ripe for a pullback. SO I'll hold off for a while.

Eccles04 - "I have never paid any such fees, not even when I started, maybe you need to find another investment platform?"

Care to share? I hate paying the exorbitant Fidelity and Halifax fees.

I'm invested in $SMT and $LGEN purely for the divi not the growth.

Been pretty stagnant for years despite some lofty analyst PT's.

What you do with the dividend is your choice. I bank the cash rather than DRIP. That cash helps to pay my ISA management fees and then depending on the pot I build, I invest it elsewhere rather than reinvesting back in LGEN or MNG. I'm aware the belief that compounding gives greater returns, but I'm a believer not to have all your eggs in one basket.

I'm an $SMT investor. Bought at 800p thinking a 50pc chop from peak was as bad as it was going to get given the trust's history. But the more I dig into it, the more I see a need to exit if it gets back above 800p.

The near 20pc discount to NAV is a sign of the market's confidence (of lack of) in the trust. NAV tracks the individual components (with good correlation), but the SP which is what us retails buy, is based in market sentiment. That discount isn't a good endorsement.

Some is due to unlisted companies they own in the trust, and some is due to buying stock at their peaks and falling SP's on some of their main holdings.

There's been some boardroom argie bargies and that's not helped. What may have been once a solid backed horse, is looking not so solid. Their fund team look under experienced and their constituent holdings and proportions seem to reflect that. Are they just pure gambling, thinking just because they're SMT, anything they buy turns to gold? It seems that way at the moment, and investors need to apply some pressure on them to make sure they take their responsibilities seriously.

The one positive thing for SMT on the horizon is the US seems very close to peak rates.

Lordloadsoflolly

Not even one more post ??

Puh-lease!

Deutsche Bank cuts M&G price target to 220 (230) pence - 'hold'

DB more realistic with the ones below.

Barclays cuts Legal & General price target to 330 (375) pence - 'overweight'

----------

Deutsche Bank cuts Legal & General target to 275 (290) pence - 'hold'

----------

Lordloadsoflolly

Cyclical? $MRNA is not cyclical. It was given a massive 'By' when COVID happened and they were allowed to fast track their vaccine. Not questioning the vaccine, but the World was desperate back then and money was thrown from all directions at any company involved in therapeutics and vaccines.

That phase has gone and we're back to the underlying pipeline (excluding -COVID). So you have to rate $MRNA on the cash on hand and their pipeline as well as their ability to succeed (which is still only 1 product). Can they execute and also price their products to satisfy the market appetite for this technology?

SMT's management are responsible for doing their due diligence on the stocks they plough funds into . Whilst the NAV should theoretically track the underlying SP's, the SP of SMT will be correlated somewhat to NAV and the investor's confidence of the management team.

(PS : I'm glad to see $MRNA is no longer the top holding as of 30th June 2023. ASML is a better choice. They should divest $ILMN....too much controversy and lack of innovation. Surprised they didn't have a big pharma like $LLY or $MRK. Would also like to see $ON on that list since they're business is growing down many avenues where there is a need or their semi's. If they need speculative stocks, then look no further than the obesity market. But individual players have had mixed success there.)